You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202181 - 202190 of 207728 results
  1. Novel Biodegradable Injectable Rod for Improved AMD Therapy

    SBC: Graybug Vision, Inc.            Topic: NEI

    ABSTRACT Age-related macular degeneration (AMD) is the leading cause of blindness in older adults with the neovascular form of the disease (NVAMD) mainly responsible for severe vision loss. Current NVAMD treatments involve repeated intraocular injections of biologics that neutralize vascular endothelial growth factor (VEGF), an important NV stimulus. Aflibercept, approved in late 2011, provides an ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Sterculic Acid Analogs to Inhibit Macular Degeneration

    SBC: L2 DIAGNOSTICS LLC            Topic: NEI

    ABSTRACT The long-term product goal of this project is a small molecule therapeutic for choroidal neovascularization (CNV, the hallmark of wet age-related macular degradation), an abnormal growth of blood vessels in the choroid layer of the eye that results in damage to the retina and consequent blindness. Our lead compound is the natural product sterculic acid, which has been shown to inhibit ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Designed Host Defense Peptides for the Treatment of Bacterial Keratitis

    SBC: Riptide Bioscience, Inc.            Topic: NEI

    DESCRIPTION (provided by applicant): Bacterial keratitis, due to its potential to cause irreversible blindness, requires prompt intervention. In the United States there are approximately 30,000 patients annually, with contact lens wear being the prime riskfactor. Bacterial keratitis i presently treated with antibiotics however innovation in antimicrobial agents and treatment is needed due to the r ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Development of SAgA Therapy for clearance of NMO-IgG in patients with neuromyelit

    SBC: Orion BioScience Inc            Topic: NEI

    DESCRIPTION (provided by applicant): Orion BioScience Inc. has developed a Soluble Antigen Array (SAgA) therapeutic that displays multiple copies of aquaporin-4 epitope for targeted clearance of the auto reactive NMO-IgG antibody in patients with neuromyelitis optica (NMO). The product is intended to selectively clear NMO-IgG while limiting interaction with other non-NMO specific antibodies, the ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Retinal Prosthesis with Enhanced Thermal Imaging

    SBC: ADVANCED MEDICAL ELECTRONICS CORP            Topic: NEI

    DESCRIPTION (provided by applicant): We propose to develop and evaluate the utility of a thermal imaging system as an input modality to a retinal prosthetic. Retinal prostheses restore partial vision to people blinded by outer retinal degenerative diseasessuch as Retinitis Pigmentosa (RP) or Macular Degeneration. The Argus II Retinal Prosthesis System is intended to provide electrical stimulation ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Sign Finding and Reading SFAR on GPU Accelerated Mobile Devices

    SBC: LYNNTECH INC.            Topic: NEI

    DESCRIPTION (provided by applicant): The inability to access information on printed signs directly impacts the mobility independence of the over 1.2 million blind persons in the U.S. Many previously proposed technological solutions to this problem either required physical modifications to the environment (talking signs or the placement of coded markers) or required the user to carry around special ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Cost-Effective OCT Detection of Vision-Threatening Macular Edema

    SBC: AEON IMAGING LLC            Topic: NEI

    DESCRIPTION (provided by applicant): I The overall goal of the proposed SBIR program is to implement and evaluate a low cost, portable retinal camera, the Digital Light Ophthalmoscope (DLO), with retinal thickness measurement functionality provided by optical coherence tomography (OCT). The combined DLO-OCT system will cost-effectively identify patients with vision-threatening macular edema for r ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. A novel prodrug for K+-ATP channel activation in the glaucomatous eye

    SBC: RADIKAL THERAPEUTICS, INC.            Topic: NEI

    DESCRIPTION (provided by applicant): Radikal Therapeutics (RTX) is developing a revolutionary bifunctional small molecule (R-801) for topical therapy of primary open angle glaucoma (POAG). R-801 is constructed from the covalent fusion of 2 chemical domains, each with demonstrated tissue protective properties: 1) a mito-K+-ATP channel activating moiety derived from the isoform non-selective K+-ATP ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Improving Blind People's Graphical Information Literacy

    SBC: VIEWPLUS TECHNOLOGIES, INC.            Topic: NEI

    DESCRIPTION (provided by applicant): This Phase I proposal is to develop audio-tactile reading technologies. These should greatly improve access by blind people to typical graphs, charts, and diagrams in modern news, business, or scientific literature. Such access could dramatically improve their educational and professional opportunities. Quality of life for blind people is a mission of the Nat ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Controlled release of a multi-functional therapeutic for the treatment of AMD

    SBC: Graybug Vision, Inc.            Topic: NEI

    DESCRIPTION (provided by applicant): Age-related macular degeneration (AMD) is the leading cause of blindness in older adults. The neovascular form of the disease (NVAMD) is primarily responsible for severe vision loss. Current NVAMD treatments involve repeated intraocular injections of biologics that neutralize vascular endothelial growth factor (VEGF), an important neovascular (NV) stimulus. Afl ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government